MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
Fiona C. Brown(Walter and Eliza Hall Institute of Medical Research), Alex Kentsis(Memorial Sloan Kettering Cancer Center)
Cited by 8
Related Papers
Peptidomimetic blockade of MYB in acute myeloid leukemia
|Nature Communications|2018|95
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|34
Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
|JCI Insight|2019|29
Peptidomimetic blockade of MYB in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|11